19.89

0.70% -0.14

Pre-market: 18.41 -1.48 -7.44%

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $19.89, with a volume of 400.37K. It is down -0.70% in the last 24 hours and up +15.71% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Previous Close:

$20.03

Open:

$19.98

24h Volume:

400.37K

Relative Volume:

1.45

Market Cap:

$896.44M

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-10.52

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

+8.87%

1M Performance:

+15.71%

6M Performance:

-20.18%

1Y Performance:

-16.67%

1-Day Range:

$19.53

$20.96

1-Week Range:

$17.98

$20.96

52-Week Range:

$13.30

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1149)

Industry

Biotechnology (673)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	19.89	896.44M	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	421.16	111.66B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	571.36	60.56B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	532.27	38.04B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	267.55	36.06B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	219.95	25.10B	3.81B	-644.79M	-669.77M	-6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

08:07 AM

Enliven Therapeutics stock target raised to $40 at H.C. Wainwright By Investing.com - Investing.com India

08:07 AM

03:30 AM

Tower Research Capital LLC TRC Boosts Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

03:30 AM

May 14, 2025

Enliven Reports Breakthrough: 44% Response Rate in CML Drug Trial Surpasses Expectations - Stock Titan

May 14, 2025

Enliven reports positive Phase 1 trial data for ELVN-001 in CML By Investing.com - Investing.com South Africa

May 14, 2025

Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile - marketscreener.com

May 14, 2025

Enliven reports positive Phase 1 trial data for ELVN-001 in CML - Investing.com Australia

May 14, 2025

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress - The Malaysian Reserve

May 14, 2025

May 11, 2025

(ELVN) Investment Analysis - news.stocktradersdaily.com

May 11, 2025

Enliven Therapeutics (ELVN) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

May 05, 2025

Wells Fargo & Company MN Has $375,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 05, 2025

Invesco Ltd. Buys 508 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 05, 2025

May 04, 2025

Barclays PLC Has $1.45 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 04, 2025

May 02, 2025

Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling - Defense World

May 02, 2025

JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 02, 2025

May 01, 2025

Enliven (ELVN) Gains Attention as EHA Data Release Approaches | - GuruFocus

May 01, 2025

Trading (ELVN) With Integrated Risk Controls - news.stocktradersdaily.com

May 01, 2025

Apr 30, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Lowered by Legal & General Group Plc - Defense World

Apr 30, 2025

Apr 24, 2025

Enliven Therapeutics chief scientific officer sells $80,365 in stock By Investing.com - Investing.com India

Apr 24, 2025

Enliven Therapeutics chief scientific officer sells $80,365 in stock - Investing.com Australia

Apr 24, 2025

Apr 23, 2025